- Home
- MUFG vs AZN Comparison
MUFG vs AZN Comparison
Compare MUFG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | AZN |
|---|---|---|
| Founded | 1880 | 1992 |
| Country | Japan | United Kingdom |
| Employees | 178953 | 96100 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.2B | 316.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MUFG | AZN |
|---|---|---|
| Price | $20.18 | $177.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 1.9M |
| Earning Date | 05-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.32% | 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.62 | $10.34 |
| Revenue Next Year | $10.12 | $6.43 |
| P/E Ratio | ★ $25.47 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.20 | $68.62 |
| 52 Week High | $20.23 | $212.71 |
Technical Indicators
Market Signals| Indicator | MUFG | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 67.79 | 41.16 |
| Support Level | $14.80 | $174.60 |
| Resistance Level | N/A | $191.50 |
| Average True Range (ATR) | 0.31 | 3.19 |
| MACD | 0.04 | -0.21 |
| Stochastic Oscillator | 89.70 | 18.27 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.